A detailed history of North Rock Partners, LLC transactions in Exact Sciences Corp stock. As of the latest transaction made, North Rock Partners, LLC holds 3,040 shares of EXAS stock, worth $182,704. This represents 0.02% of its overall portfolio holdings.

Number of Shares
3,040
Holding current value
$182,704
% of portfolio
0.02%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 30, 2024

BUY
$42.43 - $70.83 $128,987 - $215,323
3,040 New
3,040 $206,000
Q2 2023

Aug 02, 2023

SELL
$62.68 - $95.05 $55,409 - $84,024
-884 Reduced 26.8%
2,415 $226,000
Q1 2023

May 03, 2023

BUY
$47.19 - $70.77 $155,679 - $233,470
3,299 New
3,299 $223,000
Q2 2022

Aug 04, 2022

SELL
$35.61 - $76.23 $106,153 - $227,241
-2,981 Closed
0 $0
Q1 2022

May 05, 2022

BUY
$57.56 - $82.54 $171,586 - $246,051
2,981 New
2,981 $208,000

Others Institutions Holding EXAS

About EXACT SCIENCES CORP


  • Ticker EXAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 176,960,000
  • Market Cap $10.6B
  • Description
  • Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...
More about EXAS
Track This Portfolio

Track North Rock Partners, LLC Portfolio

Follow North Rock Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of North Rock Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on North Rock Partners, LLC with notifications on news.